Lumosa Therapeutics Co. Ltd.
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; L… Read more
Lumosa Therapeutics Co. Ltd. (6535) - Total Assets
Latest total assets as of December 2025: NT$1.65 Billion TWD
Based on the latest financial reports, Lumosa Therapeutics Co. Ltd. (6535) holds total assets worth NT$1.65 Billion TWD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lumosa Therapeutics Co. Ltd. - Total Assets Trend (2019–2025)
This chart illustrates how Lumosa Therapeutics Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lumosa Therapeutics Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Lumosa Therapeutics Co. Ltd.'s total assets of NT$1.65 Billion consist of 58.5% current assets and 41.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 11.0% |
| Accounts Receivable | NT$12.90 Million | 0.8% |
| Inventory | NT$98.78 Million | 6.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Lumosa Therapeutics Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lumosa Therapeutics Co. Ltd.'s current assets represent 58.5% of total assets in 2025, an increase from 0.1% in 2019.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 12.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 5.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 6.0% of total assets.
Lumosa Therapeutics Co. Ltd. Competitors by Total Assets
Key competitors of Lumosa Therapeutics Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lumosa Therapeutics Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lumosa Therapeutics Co. Ltd. generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lumosa Therapeutics Co. Ltd. is currently not profitable relative to its asset base.
Lumosa Therapeutics Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.37 | 7.64 | 6.97 |
| Quick Ratio | 6.62 | 7.15 | 6.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$835.06 Million | NT$ 1.34 Billion | NT$ 1.18 Billion |
Lumosa Therapeutics Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Lumosa Therapeutics Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.37 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | -22.6% |
| Total Assets | NT$1.65 Billion |
| Market Capitalization | $402.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lumosa Therapeutics Co. Ltd.'s assets below their book value (0.24 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lumosa Therapeutics Co. Ltd.'s assets decreased by 22.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lumosa Therapeutics Co. Ltd. (2019–2025)
The table below shows the annual total assets of Lumosa Therapeutics Co. Ltd. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.65 Billion | -22.63% |
| 2024-12-31 | NT$2.13 Billion | +28.78% |
| 2023-12-31 | NT$1.66 Billion | -12.17% |
| 2022-12-31 | NT$1.89 Billion | -19.71% |
| 2021-12-31 | NT$2.35 Billion | +31.63% |
| 2020-12-31 | NT$1.78 Billion | +34.74% |
| 2019-12-31 | NT$1.32 Billion | -- |